Podcast: Download (Duration: 15:22 — 13.6MB) | Embed
Subscribe: Spotify | Email | TuneIn | RSS | More
Q BioMed (OTCQB: QBIO) (“the Company”) CEO Denis Corin called in to SmallCapVoice.com to discuss the recent news and events for the Company. The Company recently announced the initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone. Q BioMed announced the US-based launch of Strontium89 (Strontium Chloride Sr-89 Injection, USP), in Q1 of this year.
Q BioMed is deploying a robust multi-channel marketing campaign, driving awareness amongst its target audiences, both on the physician and the patient side. The Company will exhibit Strontium89 at several conferences including ASTRO (American Society of Therapeutic Radiation Oncology) and ONS (Oncology Nursing Society) and will begin speaker programs later this fall. Virtual and live sales calls have been ongoing since June within the confines of COVID-19 access and expanded field force efforts are planned for Q4 2020.
In other news, QBIO announced a COVID-19 clinical trial planned for Q1 2021 supported by Canadian Government. Proof of concept would validate platform for multiple indications and therapeutic alternatives in infectious diseases and others.
Q BioMed CEO Denis Corin stated, “This program is advancing very rapidly. We are very pleased with the input and support from government institutions and other industry stakeholders. There has been much talk of vaccines, but treatments are always going to be needed for people affected by these types of diseases, whether it’s SARS-Cov-2 or another pathogen resulting in similar symptoms and complications. The Mannin Tie2 platform is designed to address life threatening complications from a number of infectious diseases, including future potential viral threats. With the support of regulators we expect this treatment to be in the clinic very early next year.”
